Minimum effective doses of @entity1767 for the treatment of first @entity716 : a comparative study with @entity1090 and XXXX .

@entity1 @entity308 @entity716 @entity1767 @entity1037 @entity1090
Minimum doses of @entity1767 might show similar efficacy and side-effects compared to atypical antipsychotics. The objectives of this study were to compare the efficacy of minimum doses of @entity1767 with standard doses of @entity1090 and @entity1037 on a 6-month open trial in first @entity716 @entity1 and to examine the effect of compliance on their outcome. Forty-two @entity1 were recruited and started on flexible doses of these drugs. @entity1037 was given with no cost to the @entity1 . Efficacy and side-effects were monitored every 3 months using standardized assessments. Thirty @entity1 completed the study. All treatment groups showed improvement in positive, negative and @entity308 . There were no differences in side-effects among them. The @entity1767 group required higher doses of anticholinergics. The rate of treatment discontinuation was higher in the @entity1090 group due to the direct cost. Minimum doses of @entity1767 might prove to be a good choice of treatment for @entity1 with a first episode of @entity716 .
